Financial & SEC Reports
Here you will find a summary of Celldex Therapeutics, Inc.'s latest financial information.
Copyright Morningstar
FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.
Investor Relations Contacts
Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration
More →
✓
Facebook
Twitter
Google+
Pinterest
Email
LinkedIn
Reddit
Tumblr
WordPress
Google Gmail
WhatsApp
StumbleUpon
AIM
Amazon Wish List
AOL Mail
Balatarin
BibSonomy
Bitty Browser
Blinklist
Blogger Post
BlogMarks
Bookmarks.fr
Box.net
BuddyMarks
Buffer
Care2 News
CiteULike
Copy Link
Delicious
Design Float
Diary.Ru
Diaspora
Digg
diHITT
Diigo
Douban
Draugiem
DZone
Evernote
Facebook Messenger
Fark
Flipboard
Folkd
Google Bookmarks
Google Classroom
Hacker News
Hatena
Houzz
Instapaper
Jamespot
Kakao
Kik
Kindle It
Known
Line
LiveJournal
Mail.Ru
Mendeley
Meneame
Mixi
MySpace
Netlog
Netvouz
NewsVine
NUjij
Odnoklassniki
Oknotizie
Outlook.com
Papaly
Pinboard
Plurk
Pocket
Polyvore
Print
PrintFriendly
Protopage Bookmarks
Pusha
Qzone
Rediff MyPage
Refind
Renren
Segnalo
Sina Weibo
SiteJot
Skype
Slashdot
SMS
StockTwits
Stumpedia
Svejo
Symbaloo Feeds
Telegram
Threema
Trello
Tuenti
Twiddla
TypePad Post
Viadeo
Viber
VK
Wanelo
Webnews
WeChat
Wykop
XING
Yahoo Bookmarks
Yahoo Mail
Yahoo Messenger
Yoolink
YouMob
Yummly
About us
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Our Pipeline
About
Investors & Media
© 2018 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact